Leann Blankenship
Hematology/Oncology · Pleasant Hill
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Office
- 1
- Since medical school
- 14 years
- Graduated 2012
Offices
1 location · Epic Care · 54 clinicians in this group
Hospitals listed: Alta Bates Summit Medical Center · Alta Bates Summit Medical Center - Alta Bates Camp · Contra Costa Regional Medical Center · John Muir Medical Center - Concord Campus · John Muir Medical Center - Walnut Creek Campus. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Leann Blankenship’s office at (925) 687-2570 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
- Contra Costa Regional Medical CenterMartinez, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Contra Costa Health ServicesPatients rate it 3 of 5 · 73% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.167, Oct 2024 – Sep 2025
- John Muir Medical Center - Concord CampusConcord, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of John Muir Health, which runs 3 hospitalsPatients rate it 3 of 5 · 77% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.235, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.675, Oct 2024 – Sep 2025
- John Muir Medical Center - Walnut Creek CampusWalnut Creek, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of John Muir Health, which runs 3 hospitalsPatients rate it 3 of 5 · 77% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Abdominopelvic accidental puncture or laceration rate: 2.01 (1.17 to 2.85) · 2,206 cases, Jul 2022 – Jun 2024Worse than the national rate — Death rate among surgical inpatients with serious treatable complications: 222.42 (177.82 to 267.02) · 120 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.4 (0.91 to 1.9) · 9,764 cases, Jul 2022 – Jun 2024Worse than the national rate — SSI - Colon Surgery: 2.734, Oct 2024 – Sep 2025Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.536, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.341, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.455, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.245, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.09 (87.72 to 172.46) · 109 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.227 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0.06 to 1.94) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.6 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,811 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 7,167 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,659 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (0.92 to 4.94) · 1,668 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.25 (0 to 2.75) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.19 to 4.15) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.17 (0.33 to 12.02) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.11 (4.67 to 11.55) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 0.96) · 6,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 217 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.724 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.425 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 416 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 606 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.4 · 359 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.8 · 555 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.4 · 358 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.3 to 16) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.1 to 20) · 251 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (535 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Contra Costa Regional Medical Center
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 1 better, 4 the same, 1 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.167 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.99 (0 to 2.04) · 188 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.08 (0.63 to 1.53) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.8 · 111 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.4 · 114 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.3 · 27 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 321 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.44) · 1,181 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.47) · 1,198 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.2 (0.67 to 5.72) · 216 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0 to 3.36) · 71 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.5 (0.82 to 4.18) · 195 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.36 (1.01 to 19.71) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.88 (0.69 to 9.08) · 57 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.07 (0.55 to 3.58) · 67 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.93 (0 to 2.03) · 981 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.948 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 2.027 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.3 · 101 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 52.2 · 126 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -53.6 · 112 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 87 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.7 to 8.6) · 95 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (8.8 to 17.8) · 95 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 35 cases | None | Jul 2023 – Jun 2025 |
What patients said (521 patients answered, 10% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 79% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 66% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 78% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 45% |
| "YES", patients would definitely recommend the hospital | 73% |
| Staff "always" explained possible side effects | 54% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for John Muir Medical Center - Concord Campus
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.235 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.675 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.11 (0.21 to 2) · 1,612 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.77 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 184.13 (136.65 to 231.6) · 86 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.2 · 175 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.6 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.4 · 172 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8 · 537 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.5 · 434 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 13 · 215 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 3,208 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.32 (0.13 to 0.51) · 7,626 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.04 to 0.41) · 8,660 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.1 (1.29 to 4.91) · 2,723 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.21 (0 to 2.51) · 1,208 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 3 (1.7 to 4.3) · 2,355 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.77 (3.24 to 12.3) · 1,216 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 3.43 (0.43 to 6.43) · 1,253 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.93 (0.47 to 3.4) · 388 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.14 (0.58 to 1.69) · 6,288 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.1 · 263 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.636 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.254 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.904 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.5 · 312 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.1 · 768 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -6.8 · 295 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.1 · 648 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 31.1 · 433 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 504 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.7 (5.1 to 8.8) · 476 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.9 (10.5 to 15.7) · 476 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 8.8 · 154 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.7 · 186 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (9.9 to 17.9) · 192 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.2) · 546 cases | No different | Jan 2024 – Dec 2024 |
What patients said (521 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
See every measure and the patient survey for John Muir Medical Center - Walnut Creek Campus
Behind the star rating — Deaths: 3 better, 2 the same, 2 worse of 7 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 3 better, 5 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 2.01 (1.17 to 2.85) · 2,206 cases | Worse | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 222.42 (177.82 to 267.02) · 120 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.4 (0.91 to 1.9) · 9,764 cases | Worse | Jul 2022 – Jun 2024 |
| SSI - Colon SurgeryInfections | 2.734 | Worse | Oct 2024 – Sep 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.536 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.341 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.455 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.245 | Better | Oct 2024 – Sep 2025 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.87 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 131 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 148 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 695 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.5 · 827 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 14.1 · 509 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 4,483 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.35 (0.18 to 0.53) · 11,630 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.05 to 0.39) · 11,793 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.69 to 4.96) · 3,268 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.37 (0 to 2.94) · 1,631 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.76 (1.43 to 4.09) · 3,066 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.12 (0.22 to 12.02) · 1,580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.43 (1.21 to 7.64) · 1,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.82 (0.4 to 3.24) · 685 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 615 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 1.88 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 93 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 729 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.1 · 91 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13 · 736 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 34.8 · 842 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.7 · 818 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.3 to 8.4) · 28 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.2 to 15.5) · 28 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 584 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.4 · 139 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.9) · 222 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 321 cases | No different | Jan 2024 – Dec 2024 |
What patients said (758 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$2,829,682
Medicare paid this office $2,829,682 for 717 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, denosumab, 1 mg | 41 | $151,428 | None |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 42 | $104,493 | $1,771 |
| Telephone medical discussion with physician, 21-30 minutes | 304 | $64,248 | $116 |
| Return visit (30+ min) | 342 | $62,256 | $109 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 12 | $41,858 | $6 |
See all 47 services
| Injection, denosumab, 1 mg | 41 | $151,428 | None |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 42 | $104,493 | $1,771 |
| Telephone medical discussion with physician, 21-30 minutes | 304 | $64,248 | $116 |
| Return visit (30+ min) | 342 | $62,256 | $109 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 12 | $41,858 | $6 |
| Administration of chemotherapy into vein, 1 hour or less | 38 | $37,506 | $132 |
| Injection, ferric derisomaltose, 10 mg | 18 | $36,238 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 91 | $17,922 | $69 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 45 | $17,730 | $281 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 30 | $13,190 | $29 |
| Long return visit (40+ min) | 57 | $11,098 | $161 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 69 | $10,874 | $147 |
| Ct scan of abdomen and pelvis with contrast | 22 | $9,056 | $312 |
| Injection of drug or substance under skin or into muscle | 84 | $7,645 | $14 |
| Insertion of needle into vein for collection of blood sample | 266 | $7,603 | $9 |
| Injection, aprepitant, 1 mg | 12 | $7,475 | None |
| New patient visit (45+ min) | 49 | $7,147 | $146 |
| New patient visit (60+ min) | 36 | $7,049 | $196 |
| Ct scan of chest with contrast | 25 | $6,041 | $178 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 230 | $5,685 | $8 |
| Administration of additional new drug or substance into vein, 1 hour or less | 15 | $5,622 | $68 |
| Administration of additional new drug or substance into vein using push technique | 11 | $5,599 | $58 |
| Mri scan of both breasts | 13 | $4,595 | $353 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $4,509 | $105 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 30 | $4,193 | $65 |
| Mri scan of brain before and after contrast | 12 | $4,171 | $321 |
| Telephone medical discussion with physician, 11-20 minutes | 44 | $3,400 | $69 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 26 | $3,253 | $20 |
| Ct scan of chest without contrast | 22 | $2,849 | $119 |
| Irrigation of implanted venous access drug delivery device | 18 | $2,785 | $25 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $2,482 | $36 |
| Ct scan of abdomen and pelvis without contrast | 12 | $2,416 | $186 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 42 | $2,277 | $43 |
| Drawing of blood for a medical problem | 11 | $2,049 | $102 |
| Administration of chemotherapy into vein, each additional hour | 14 | $1,655 | $29 |
| Short return visit (20+ min) | 17 | $1,341 | $79 |
| Injection of drug or substance into vein | 20 | $1,042 | $37 |
| Injection, palonosetron hcl, 25 mcg | 23 | $1,012 | None |
| Injection, zoledronic acid, 1 mg | 19 | $974 | None |
| Injection of additional new drug or substance into vein | 19 | $808 | $16 |
| Injection, gadobutrol, 0.1 ml | 34 | $785 | $0 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 26 | $360 | $0 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 23 | $325 | $14 |
| Blood count, hemoglobin | 16 | $216 | $2 |
| Injection, dexamethasone sodium phosphate, 1 mg | 24 | $216 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 14 | $95 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 19 | $70 | None |
Who their Medicare patients are
717 Original Medicare patients in 2024. Average age 74 · Under 65 9% · 85 and older 12% · Women 67% · Also on Medicaid 36% · Health risk score 2.03. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Cancer 56% · Chronic kidney disease 34% · Diabetes 32% · Depression 23% · Coronary heart disease 22% · Heart failure 19% · COPD 19% · Atrial fibrillation 17% · Stroke 9% · Dementia 6%.
The office billed $11,939,729, Medicare allowed $3,570,437 and paid $2,829,682; for 192,980 services of 138 kinds; $2,324,999 of it was for drugs given in the office and $504,682 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 717 | 192,980 | 74 | 2.03 | $11,939,729 | $2,829,682 |
| 2023 | 558 | 187,051 | 74 | 2.10 | $11,821,810 | $2,576,726 |
| 2022 | 498 | 144,844 | 74 | 1.96 | $7,620,367 | $1,848,279 |
| 2021 | 590 | 92,729 | 74 | 2.67 | $2,840,786 | $1,172,029 |
| 2020 | 565 | 114,425 | 74 | 3.04 | $2,703,505 | $1,659,437 |
| 2019 | 731 | 71,980 | 74 | 2.57 | $1,859,323 | $1,148,677 |
| 2018 | 226 | 8,727 | 74 | 2.68 | $264,912 | $165,518 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 38 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 45 | $111,858 | $1,695 |
| Injection, denosumab, 1 mg | 29 | $104,219 | None |
| Return visit (30+ min) | 251 | $50,542 | $105 |
| Telephone medical discussion with physician, 21-30 minutes | 242 | $48,279 | $81 |
| Injection, ferric derisomaltose, 10 mg | 22 | $43,834 | None |
| Administration of chemotherapy into vein, 1 hour or less | 39 | $40,398 | $135 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 48 | $20,248 | $281 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 35 | $16,480 | $30 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 100 | $16,274 | $70 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 59 | $8,880 | $151 |
| Ct scan of abdomen and pelvis with contrast | 18 | $8,745 | $324 |
| Administration of additional new drug or substance into vein, 1 hour or less | 23 | $8,705 | $67 |
| Long return visit (40+ min) | 39 | $8,414 | $162 |
| New patient visit (45+ min) | 49 | $7,195 | $147 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 207 | $6,628 | $8 |
| Injection of drug or substance under skin or into muscle | 71 | $6,307 | $13 |
| Insertion of needle into vein for collection of blood sample | 202 | $5,846 | $8 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $5,695 | $104 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 32 | $4,966 | $65 |
| Ct scan of chest with contrast | 17 | $4,810 | $178 |
| Ct scan of chest without contrast | 23 | $4,611 | $128 |
| Mri scan of both breasts | 12 | $4,177 | $348 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 32 | $3,914 | $20 |
| New patient visit (60+ min) | 18 | $3,709 | $206 |
| Administration of chemotherapy into vein, each additional hour | 15 | $2,440 | $29 |
| Drawing of blood for a medical problem | 12 | $2,415 | $97 |
| Irrigation of implanted venous access drug delivery device | 17 | $1,777 | $27 |
| Injection, fosaprepitant, 1 mg | 19 | $1,752 | None |
| Injection, palonosetron hcl, 25 mcg | 27 | $1,385 | None |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 18 | $1,337 | $41 |
| Telephone medical discussion with physician, 11-20 minutes | 27 | $1,168 | $39 |
| Injection, zoledronic acid, 1 mg | 15 | $1,086 | None |
| Injection, gadobutrol, 0.1 ml | 24 | $668 | $0 |
| Injection of drug or substance into vein | 11 | $593 | $35 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 21 | $355 | $0 |
| Injection, dexamethasone sodium phosphate, 1 mg | 31 | $274 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 22 | $137 | None |
| Unclassified drugs | 16 | $73 | None |
2022: 43 services
| Injection, denosumab, 1 mg | 24 | $117,536 | None |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 40 | $84,549 | $1,658 |
| Return visit (30+ min) | 265 | $57,736 | $108 |
| Telephone medical discussion with physician, 21-30 minutes | 211 | $40,307 | $86 |
| Administration of chemotherapy into vein, 1 hour or less | 34 | $32,408 | $140 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 26 | $18,652 | $1 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 96 | $16,348 | $63 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 40 | $14,451 | $283 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 31 | $11,648 | $30 |
| Long return visit (40+ min) | 35 | $10,231 | $168 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 55 | $9,929 | $171 |
| New patient visit (45+ min) | 59 | $8,049 | $136 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 188 | $6,776 | $8 |
| Ct scan of abdomen and pelvis with contrast | 15 | $6,492 | $325 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 39 | $6,390 | $70 |
| Injection of drug or substance under skin or into muscle | 54 | $4,585 | $13 |
| Administration of additional new drug or substance into vein, 1 hour or less | 13 | $4,318 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $4,143 | $90 |
| New patient visit (60+ min) | 18 | $3,704 | $206 |
| Ct scan of chest with contrast | 16 | $3,388 | $169 |
| Administration of chemotherapy into vein, each additional hour | 15 | $2,944 | $29 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 25 | $2,661 | $20 |
| Telephone medical discussion with physician, 11-20 minutes | 27 | $1,714 | $55 |
| Insertion of needle into vein for collection of blood sample | 172 | $1,610 | $3 |
| Extended office or other outpatient service, first hour | 13 | $1,472 | $113 |
| Injection, fosaprepitant, 1 mg | 12 | $1,232 | None |
| Infusion into a vein for hydration, 31-60 minutes | 11 | $1,188 | $34 |
| Blood test, comprehensive group of blood chemicals | 62 | $1,181 | $10 |
| Advance care planning, first 30 minutes | 16 | $1,127 | $66 |
| Injection of drug or substance into vein | 14 | $767 | $40 |
| Injection, palonosetron hcl, 25 mcg | 18 | $760 | None |
| Injection, zoledronic acid, 1 mg | 15 | $633 | None |
| Injection, gadobutrol, 0.1 ml | 18 | $486 | $0 |
| Lactate dehydrogenase (enzyme) level | 29 | $371 | $6 |
| Ferritin (blood protein) level | 22 | $351 | $13 |
| Cyanocobalamin (vitamin b-12) level | 16 | $314 | $15 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 20 | $246 | $0 |
| Uric acid level, blood | 21 | $223 | $4 |
| Folic acid level, serum | 11 | $204 | $15 |
| Injection, dexamethasone sodium phosphate, 1 mg | 27 | $177 | None |
| Iron level | 16 | $148 | $6 |
| Injection, diphenhydramine hcl, up to 50 mg | 22 | $110 | None |
| Unclassified drugs | 16 | $49 | None |
2021: 39 services
| Return visit (30+ min) | 216 | $43,893 | $113 |
| Injection, denosumab, 1 mg | 21 | $39,742 | None |
| Injection, pegfilgrastim, 6 mg | 12 | $34,160 | None |
| Administration of chemotherapy into vein, 1 hour or less | 87 | $21,883 | $128 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 104 | $21,637 | $86 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 71 | $12,909 | $168 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 22 | $12,031 | $7 |
| Injection, ferric carboxymaltose, 1 mg | 14 | $11,200 | None |
| Long return visit (40+ min) | 45 | $10,332 | $150 |
| Telephone medical discussion with physician, 21-30 minutes | 44 | $7,235 | $123 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 70 | $6,772 | $28 |
| Short return visit (20+ min) | 69 | $6,479 | $71 |
| New patient visit (60+ min) | 25 | $4,715 | $189 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 160 | $4,149 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 38 | $3,707 | $63 |
| New patient visit (45+ min) | 23 | $3,631 | $158 |
| Blood test, comprehensive group of blood chemicals | 128 | $3,580 | $11 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 34 | $3,564 | $64 |
| Administration of additional new drug or substance into vein, 1 hour or less | 27 | $2,785 | $61 |
| Return visit (30+ min) | 24 | $2,401 | $77 |
| Administration of chemotherapy into vein, each additional hour | 32 | $1,933 | $27 |
| Injection of drug or substance under skin or into muscle | 73 | $1,920 | $12 |
| Injection, fosaprepitant, 1 mg | 32 | $1,898 | None |
| Administration of additional new drug or substance into vein using push technique | 15 | $1,465 | $56 |
| Insertion of needle into vein for collection of blood sample | 148 | $1,443 | $3 |
| Ferritin (blood protein) level | 54 | $1,090 | $14 |
| Injection, palonosetron hcl, 25 mcg | 37 | $934 | None |
| Injection, zoledronic acid, 1 mg | 17 | $708 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 17 | $692 | $20 |
| Injection of additional new drug or substance into vein | 34 | $646 | $14 |
| Magnesium level | 12 | $268 | $7 |
| Injection, carboplatin, 50 mg | 15 | $266 | None |
| Lactate dehydrogenase (enzyme) level | 28 | $265 | $6 |
| Injection, paclitaxel, 1 mg | 11 | $246 | None |
| Application of on-body injector for under skin injection | 12 | $232 | $15 |
| Injection, dexamethasone sodium phosphate, 1 mg | 51 | $129 | None |
| Uric acid level, blood | 14 | $104 | $5 |
| Injection, diphenhydramine hcl, up to 50 mg | 29 | $25 | None |
| Unclassified drugs | 14 | $23 | None |
2020: 43 services
| Injection, pembrolizumab, 1 mg | 17 | $265,527 | None |
| Injection, pegfilgrastim, 6 mg | 25 | $124,196 | None |
| Injection, denosumab, 1 mg | 24 | $61,612 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 200 | $51,000 | $86 |
| Return visit (30+ min) | 122 | $32,833 | $86 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 38 | $30,019 | $7 |
| Administration of chemotherapy into vein, 1 hour or less | 103 | $28,939 | $113 |
| Injection, fulvestrant, 25 mg | 13 | $28,343 | None |
| Injection, ferric carboxymaltose, 1 mg | 34 | $26,028 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 121 | $22,801 | $168 |
| Long return visit (40+ min) | 71 | $16,152 | $120 |
| Injection, fosaprepitant, 1 mg | 37 | $9,902 | None |
| New patient visit (60+ min) | 50 | $8,078 | $162 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 83 | $7,638 | $24 |
| Blood test, comprehensive group of blood chemicals | 136 | $6,341 | $10 |
| Short return visit (20+ min) | 53 | $6,220 | $58 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 141 | $5,847 | $8 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $5,060 | $64 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 55 | $4,148 | $57 |
| Administration of additional new drug or substance into vein, 1 hour or less | 33 | $3,680 | $56 |
| Return visit (30+ min) | 31 | $3,144 | $64 |
| Administration of chemotherapy into vein, each additional hour | 38 | $2,737 | $25 |
| Injection, palonosetron hcl, 25 mcg | 40 | $2,345 | None |
| Insertion of needle into vein for collection of blood sample | 143 | $2,326 | $3 |
| Injection of drug or substance under skin or into muscle | 77 | $1,849 | $12 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $1,464 | $26 |
| Administration of additional new drug or substance into vein using push technique | 15 | $1,449 | $48 |
| Injection of additional new drug or substance into vein | 53 | $1,372 | $13 |
| Ferritin (blood protein) level | 50 | $1,357 | $14 |
| Injection, zoledronic acid, 1 mg | 17 | $920 | None |
| Application of on-body injector for under skin injection | 25 | $647 | $16 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 11 | $570 | None |
| Magnesium level | 27 | $520 | $7 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 13 | $358 | $17 |
| Injection, carboplatin, 50 mg | 15 | $310 | None |
| Injection, fluorouracil, 500 mg | 13 | $270 | None |
| Infusion into a vein for hydration, each additional hour | 12 | $230 | $11 |
| Lactate dehydrogenase (enzyme) level | 24 | $201 | $5 |
| Injection, dexamethasone sodium phosphate, 1 mg | 64 | $169 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 37 | $42 | None |
| Injection, potassium chloride, per 2 meq | 16 | $25 | None |
| Injection, magnesium sulfate, per 500 mg | 13 | $17 | None |
| Unclassified drugs | 11 | $12 | None |
2019: 42 services
| Injection, pegfilgrastim, 6 mg | 26 | $111,165 | None |
| Injection, denosumab, 1 mg | 20 | $45,371 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 177 | $38,531 | $84 |
| Return visit (30+ min) | 113 | $26,291 | $85 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 128 | $24,241 | $164 |
| Administration of chemotherapy into vein, 1 hour or less | 89 | $20,421 | $112 |
| Injection, ferric carboxymaltose, 1 mg | 21 | $15,756 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 22 | $14,636 | None |
| Injection, fosaprepitant, 1 mg | 35 | $10,373 | None |
| Long return visit (40+ min) | 50 | $8,314 | $114 |
| Blood test, comprehensive group of blood chemicals | 390 | $6,812 | $11 |
| New patient visit (60+ min) | 40 | $6,514 | $163 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 431 | $6,266 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 75 | $5,110 | $25 |
| Injection, palonosetron hcl, 25 mcg | 40 | $4,206 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 41 | $3,094 | $56 |
| Administration of additional new drug or substance into vein, 1 hour or less | 38 | $2,835 | $55 |
| Insertion of needle into vein for collection of blood sample | 424 | $2,166 | $3 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $2,037 | $64 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 11 | $1,964 | $123 |
| Administration of chemotherapy into vein, each additional hour | 27 | $1,787 | $24 |
| Return visit (30+ min) | 24 | $1,676 | $64 |
| Ferritin (blood protein) level | 82 | $1,381 | $15 |
| Short return visit (20+ min) | 20 | $1,336 | $58 |
| Administration of additional new drug or substance into vein using push technique | 16 | $1,263 | $47 |
| Injection of drug or substance under skin or into muscle | 50 | $1,098 | $13 |
| Injection of additional new drug or substance into vein | 47 | $908 | $13 |
| Iron binding capacity | 79 | $857 | $10 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $663 | $25 |
| Iron level | 79 | $635 | $7 |
| Magnesium level | 40 | $481 | $7 |
| Injection, zoledronic acid, 1 mg | 11 | $481 | None |
| Application of on-body injector for under skin injection | 23 | $437 | $16 |
| Lactate dehydrogenase (enzyme) level | 51 | $328 | $5 |
| Injection, carboplatin, 50 mg | 17 | $292 | None |
| Injection, paclitaxel, 1 mg | 12 | $289 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 11 | $251 | $17 |
| Injection, fluorouracil, 500 mg | 11 | $206 | None |
| Injection, ranitidine hydrochloride, 25 mg | 16 | $180 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 64 | $123 | None |
| Injection, magnesium sulfate, per 500 mg | 14 | $38 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 36 | $30 | None |
2018: 12 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 93 | $17,438 | $85 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 59 | $11,057 | $165 |
| Return visit (30+ min) | 43 | $8,382 | $87 |
| Administration of chemotherapy into vein, 1 hour or less | 17 | $3,189 | $114 |
| New patient visit (60+ min) | 18 | $3,061 | $170 |
| Long return visit (40+ min) | 15 | $2,716 | $118 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 14 | $886 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 11 | $759 | $58 |
| Blood test, comprehensive group of blood chemicals | 57 | $741 | $13 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 69 | $696 | $9 |
| Insertion of needle into vein for collection of blood sample | 70 | $221 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 13 | $15 | None |
Medicaid work
$109,821 in 2024
Medicaid paid $109,821 for 1,662 billed services this clinician did in 2024, up to 68 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 599 | $62,148 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 184 | $19,315 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 118 | $8,170 |
| Long return visit (40+ min) | 47 | $7,908 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 56 | $3,147 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 284 | $2,859 |
| New patient visit (45+ min) | 16 | $2,803 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 322 | $2,638 |
| Injection, dexamethasone sodium phosphate, 1 mg | 18 | $426 |
| Palonosetron hcl | 18 | $407 |
| 2024 | 1,662 | 10 | 68 | $109,821 |
| 2023 | 2,089 | 14 | 57 | $86,175 |
| 2022 | 831 | 5 | 35 | $36,255 |
| 2021 | 17 | 1 | 16 | $1,097 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 541 | $46,275 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 148 | $12,613 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 147 | $7,162 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 354 | $3,424 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 489 | $3,111 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 63 | $2,990 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 31 | $2,626 |
| Long return visit (40+ min) | 30 | $2,517 |
| Palonosetron hcl | 85 | $1,450 |
| New patient visit (45+ min) | 14 | $1,380 |
| 1ST HOSP IP/OBS HIGH 75 | 13 | $1,116 |
| Injection, dexamethasone sodium phosphate, 1 mg | 94 | $867 |
2022
| Return visit (30+ min) | 339 | $28,112 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 62 | $3,975 |
| New patient visit (45+ min) | 36 | $2,174 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 358 | $1,541 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 36 | $453 |
2021
| Return visit (30+ min) | 17 | $1,097 |
Drugs they prescribed that Part D paid
$3,315,976
Pharmacies billed $3,315,976 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 6% of their Part D prescriptions (102 of 1,808) in 2024. Above the middle of the specialty; the typical hematology-oncology clinician is at 5%. Long-acting opioids: 12% of their opioid prescriptions.
1,470 generic and fewer than 11 brand-name prescriptions · $3,315,976 in drug cost · 19 antibiotic prescriptions to 14 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ibrance | 44 | $652,253 | $14,824 |
| Imbruvica | 18 | $283,710 | $15,762 |
| Pomalyst | 12 | $283,523 | $23,627 |
| Tagrisso | 16 | $252,945 | $15,809 |
| Lenalidomide | 18 | $208,748 | $11,597 |
See all 37 drugs
| Ibrance | 44 | $652,253 | $14,824 |
| Imbruvica | 18 | $283,710 | $15,762 |
| Pomalyst | 12 | $283,523 | $23,627 |
| Tagrisso | 16 | $252,945 | $15,809 |
| Lenalidomide | 18 | $208,748 | $11,597 |
| Doptelet | 11 | $142,035 | $12,912 |
| Braftovi | 11 | $88,210 | $8,019 |
| Eliquis | 52 | $55,553 | $1,068 |
| Xarelto | 28 | $43,917 | $1,568 |
| Exemestane | 54 | $8,257 | $153 |
| Imatinib Mesylate | 12 | $6,583 | $549 |
| Letrozole | 272 | $6,520 | $24 |
| Ondansetron | 81 | $2,220 | $27 |
| Tamoxifen Citrate | 60 | $1,727 | $29 |
| Hydrocodone-Acetaminophen | 53 | $1,454 | $27 |
| Hydroxyurea | 36 | $1,335 | $37 |
| Anastrozole | 67 | $1,032 | $15 |
| Prochlorperazine Maleate | 80 | $972 | $12 |
| Raloxifene | 22 | $781 | $35 |
| Gabapentin | 34 | $513 | $15 |
| Dexamethasone | 30 | $488 | $16 |
| Acyclovir | 41 | $401 | $10 |
| Oxycodone | 25 | $381 | $15 |
| Pregabalin | 15 | $306 | $20 |
| Alendronate | 33 | $292 | $9 |
| Prednisone | 27 | $245 | $9 |
| Levothyroxine | 21 | $231 | $11 |
| Loperamide | 22 | $222 | $10 |
| Lorazepam | 41 | $160 | $4 |
| Pantoprazole | 25 | $133 | $5 |
| Olanzapine | 11 | $113 | $10 |
| Atorvastatin | 15 | $101 | $7 |
| Allopurinol | 14 | $101 | $7 |
| Potassium Chloride | 13 | $80 | $6 |
| Citalopram Hbr | 13 | $54 | $4 |
| Triamcinolone Acetonide | 11 | $41 | $4 |
| Levocetirizine Dihydrochloride | 11 | $8 | $1 |
Year by year
| 2024 | 1,808 | 336 | 6% (102) | None | $3,315,976 |
| 2023 | 1,522 | 295 | 6% (87) | None | $1,692,674 |
| 2022 | 1,386 | 235 | 3% (42) | None | $2,184,816 |
| 2021 | 935 | 213 | 7% (62) | None | $1,548,765 |
| 2020 | 844 | 139 | 11% (93) | None | $1,319,719 |
| 2019 | 435 | 110 | 8% (36) | 29% | $660,318 |
| 2018 | 255 | 42 | 10% (25) | 14% | $236,581 |
| 2017 | 265 | 44 | 15% (39) | 16% | $175,171 |
| 2016 | 169 | 25 | 20% (34) | None | $173,394 |
| 2015 | 36 | None | None | None | $42,115 |
| 2014 | 73 | None | 0% (0) | 15% | $4,585 |
| 2013 | 319 | 73 | None | None | $15,786 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 34 drugs
| Ibrance | 24 | $405,242 | $16,885 |
| Tagrisso | 15 | $243,901 | $16,260 |
| Imbruvica | 15 | $233,983 | $15,599 |
| Calquence | 12 | $191,233 | $15,936 |
| Eliquis | 59 | $56,786 | $962 |
| Xarelto | 28 | $40,041 | $1,430 |
| Exemestane | 58 | $9,626 | $166 |
| Letrozole | 233 | $8,266 | $35 |
| Imatinib Mesylate | 13 | $5,550 | $427 |
| Anastrozole | 45 | $2,275 | $51 |
| Hydroxyurea | 34 | $1,909 | $56 |
| Potassium Chloride | 12 | $1,892 | $158 |
| Hydrocodone-Acetaminophen | 56 | $1,264 | $23 |
| Tamoxifen Citrate | 34 | $1,242 | $37 |
| Ondansetron | 85 | $1,219 | $14 |
| Prochlorperazine Maleate | 73 | $995 | $14 |
| Dexamethasone | 50 | $835 | $17 |
| Gabapentin | 37 | $702 | $19 |
| Alendronate | 19 | $681 | $36 |
| Acyclovir | 39 | $622 | $16 |
| Raloxifene | 16 | $572 | $36 |
| Pantoprazole | 30 | $520 | $17 |
| Pregabalin | 15 | $286 | $19 |
| Lorazepam | 40 | $277 | $7 |
| Omeprazole | 12 | $260 | $22 |
| Warfarin | 21 | $222 | $11 |
| Levothyroxine | 14 | $211 | $15 |
| Oxycodone | 11 | $181 | $16 |
| Sulfamethoxazole-Trimethoprim | 11 | $151 | $14 |
| Prednisone | 20 | $124 | $6 |
| Baclofen | 16 | $122 | $8 |
| Venlafaxine Hcl Er | 12 | $114 | $9 |
| Loperamide | 11 | $97 | $9 |
| Triamcinolone Acetonide | 12 | $93 | $8 |
2022: 34 drugs
| Ibrance | 36 | $540,280 | $15,008 |
| Imbruvica | 25 | $345,477 | $13,819 |
| Xtandi | 11 | $153,575 | $13,961 |
| Verzenio | 14 | $147,142 | $10,510 |
| Abiraterone Acetate | 18 | $76,982 | $4,277 |
| Eliquis | 33 | $27,296 | $827 |
| Xarelto | 16 | $24,001 | $1,500 |
| Exemestane | 52 | $16,134 | $310 |
| Letrozole | 186 | $7,497 | $40 |
| Combivent Respimat | 12 | $5,961 | $497 |
| Anastrozole | 73 | $2,185 | $30 |
| Tamoxifen Citrate | 37 | $1,789 | $48 |
| Hydroxyurea | 35 | $1,513 | $43 |
| Ondansetron | 56 | $1,214 | $22 |
| Pregabalin | 16 | $1,138 | $71 |
| Prochlorperazine Maleate | 63 | $940 | $15 |
| Dexamethasone | 28 | $704 | $25 |
| Potassium Chloride | 19 | $559 | $29 |
| Acyclovir | 35 | $538 | $15 |
| Gabapentin | 42 | $487 | $12 |
| Hydrocodone-Acetaminophen | 30 | $473 | $16 |
| Hydroxyzine | 20 | $428 | $21 |
| Alendronate | 14 | $370 | $26 |
| Prednisone | 48 | $306 | $6 |
| Levothyroxine | 14 | $299 | $21 |
| Venlafaxine Hcl Er | 13 | $284 | $22 |
| Rosuvastatin | 11 | $266 | $24 |
| Warfarin | 25 | $243 | $10 |
| Lorazepam | 35 | $233 | $7 |
| Allopurinol | 20 | $209 | $10 |
| Pantoprazole | 29 | $185 | $6 |
| Loperamide | 13 | $134 | $10 |
| Bupropion Xl | 11 | $79 | $7 |
| Hydrochlorothiazide | 12 | $66 | $6 |
2021: 22 drugs
| Revlimid | 25 | $406,939 | $16,278 |
| Ibrance | 16 | $208,366 | $13,023 |
| Eliquis | 35 | $27,989 | $800 |
| Xarelto | 16 | $18,235 | $1,140 |
| Letrozole | 70 | $3,375 | $48 |
| Anastrozole | 58 | $1,956 | $34 |
| Potassium Chloride | 37 | $1,466 | $40 |
| Prochlorperazine Maleate | 50 | $1,123 | $22 |
| Hydroxyurea | 17 | $926 | $54 |
| Diphenoxylate-Atropine | 29 | $888 | $31 |
| Fentanyl | 17 | $827 | $49 |
| Tamoxifen Citrate | 14 | $780 | $56 |
| Gabapentin | 26 | $659 | $25 |
| Ondansetron | 22 | $629 | $29 |
| Dexamethasone | 20 | $453 | $23 |
| Hydrocodone-Acetaminophen | 14 | $340 | $24 |
| Oxycodone | 11 | $326 | $30 |
| Famotidine | 23 | $280 | $12 |
| Acyclovir | 20 | $264 | $13 |
| Prednisone | 37 | $219 | $6 |
| Pantoprazole | 15 | $122 | $8 |
| Triamcinolone Acetonide | 11 | $48 | $4 |
2020: 27 drugs
| Ibrance | 29 | $358,714 | $12,369 |
| Mektovi | 19 | $230,034 | $12,107 |
| Revlimid | 12 | $181,436 | $15,120 |
| Abiraterone Acetate | 11 | $26,400 | $2,400 |
| Xarelto | 20 | $22,690 | $1,135 |
| Eliquis | 34 | $20,907 | $615 |
| Ondansetron | 28 | $1,642 | $59 |
| Dronabinol | 16 | $1,639 | $102 |
| Fentanyl | 26 | $1,500 | $58 |
| Anastrozole | 33 | $1,236 | $37 |
| Prochlorperazine Maleate | 38 | $1,002 | $26 |
| Oxycodone-Acetaminophen | 12 | $968 | $81 |
| Hydroxyurea | 19 | $967 | $51 |
| Letrozole | 21 | $820 | $39 |
| Potassium Chloride | 39 | $787 | $20 |
| Dexamethasone | 20 | $673 | $34 |
| Diphenoxylate-Atropine | 17 | $413 | $24 |
| Hydrocodone-Acetaminophen | 22 | $341 | $16 |
| Oxycodone | 15 | $334 | $22 |
| Gabapentin | 14 | $329 | $24 |
| Amlodipine Besylate | 11 | $252 | $23 |
| Prednisone | 37 | $242 | $7 |
| Acyclovir | 20 | $115 | $6 |
| Lorazepam | 17 | $84 | $5 |
| Omeprazole | 17 | $81 | $5 |
| Triamcinolone Acetonide | 15 | $75 | $5 |
| Sulfamethoxazole-Trimethoprim | 12 | $29 | $2 |
2019: 7 drugs
| Ibrance | 17 | $201,151 | $11,832 |
| Eliquis | 11 | $4,574 | $416 |
| Potassium Chloride | 15 | $425 | $28 |
| Diphenoxylate-Atropine | 11 | $347 | $32 |
| Prochlorperazine Maleate | 21 | $336 | $16 |
| Prednisone | 30 | $254 | $8 |
| Ondansetron | 11 | $198 | $18 |
2018: 4 drugs
| Imatinib Mesylate | 12 | $85,750 | $7,146 |
| Acyclovir | 13 | $204 | $16 |
| Tamsulosin | 15 | $119 | $8 |
| Prednisone | 13 | $81 | $6 |
2017: 2 drugs
| Fenofibrate | 13 | $381 | $29 |
| Acyclovir | 13 | $246 | $19 |
2016: 1 drug
| Hydrocodone-Acetaminophen | 11 | $342 | $31 |
2013: 5 drugs
| Nexium | 16 | $3,855 | $241 |
| Famotidine | 14 | $95 | $7 |
| Metoprolol | 14 | $78 | $6 |
| Lisinopril | 11 | $56 | $5 |
| Prednisone | 18 | $41 | $2 |
Money from drug and device companies
$4,641 in 2025
| 2025 | 47 | 205 | None | $4,641 |
| 2024 | 46 | 207 | None | $4,343 |
| 2023 | 50 | 199 | None | $4,392 |
| 2022 | 36 | 158 | None | $2,923 |
| 2021 | 38 | 79 | None | $1,611 |
| 2020 | 7 | 18 | $2,800 | $4,277 |
| 2019 | 17 | 24 | None | $697 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Calquence | $530 | 21 payments
|
| Merck Sharp & Dohme | Keytruda | $370 | 13 payments
|
| Celgene | Reblozyl | $326 | 15 payments
|
| GlaxoSmithKline | Jemperli | $314 | 13 payments
|
| Janssen Biotech | Tecvayli | $298 | 11 payments
|
| Pfizer | Padcev | $233 | 10 payments
|
See all 199 published payments
| Janssen Biotech | Meals · 2025-12-23 | Rybrevant | $36 |
| Novartis Pharmaceuticals | Meals · 2025-12-22 | Scemblix | $33 |
| Syndax Pharmaceuticals | Meals · 2025-12-21 | None | $22 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-18 | Reblozyl | $30 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-18 | Reblozyl | $2 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-12-17 | Ninlaro | $1 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-12-17 | Ninlaro | $2 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-12-17 | Iclusig | $27 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-12-16 | Ninlaro | $1 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-12-16 | Ninlaro | $2 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-12-16 | Iclusig | $16 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-12 | Enhertu | $32 |
| Genmab U.S. | Meals · 2025-12-09 | Epkinly | $32 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-08 | Opdivo | $25 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-08 | Lynparza | $20 |
| Novartis Pharmaceuticals | Meals · 2025-12-03 | Kisqali | $25 |
| Agios Pharmaceuticals | Meals · 2025-12-02 | Pyrukynd | $17 |
| GlaxoSmithKline | Meals · 2025-12-01 | Jemperli | $20 |
| Abbvie | Meals · 2025-11-25 | Epkinly | $25 |
| Regeneron Healthcare Solutions | Meals · 2025-11-25 | Libtayo | $30 |
| Sobi | Meals · 2025-11-25 | Vonjo | $23 |
| Syndax Pharmaceuticals | Meals · 2025-11-24 | None | $21 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-21 | Calquence | $25 |
| SpringWorks Therapeutics | Meals · 2025-11-20 | Ogsiveo | $20 |
| Abbvie | Meals · 2025-11-18 | Venclexta | $21 |
| Array Biopharma | Meals · 2025-11-18 | Braftovi | $24 |
| Jazz Pharmaceuticals | Meals · 2025-11-17 | Zepzelca | $28 |
| Pfizer | Meals · 2025-11-14 | Elrexfio | $21 |
| Merck Sharp & Dohme | Meals · 2025-11-13 | Keytruda | $32 |
| Daiichi Sankyo | Meals · 2025-11-12 | Datroway | $21 |
| Stemline Therapeutics | Meals · 2025-11-11 | Orserdu | $27 |
| Celgene | Meals · 2025-11-07 | Reblozyl | $27 |
| Merck Sharp & Dohme | Meals · 2025-11-06 | Keytruda | $30 |
| GlaxoSmithKline | Meals · 2025-11-05 | Jemperli | $33 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-04 | Opdivo | $21 |
| PharmaEssentia USA | Meals · 2025-11-04 | Besremi | $27 |
| SpringWorks Therapeutics | Meals · 2025-11-03 | Ogsiveo | $37 |
| GlaxoSmithKline | Meals · 2025-10-31 | Ojjaara | $26 |
| Pfizer | Meals · 2025-10-30 | Padcev | $35 |
| GlaxoSmithKline | Meals · 2025-10-29 | Ojjaara | $14 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-28 | Calquence | $22 |
| GlaxoSmithKline | Meals · 2025-10-27 | Ojjaara | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-24 | Imfinzi | $27 |
| Janssen Biotech | Meals · 2025-10-23 | Erleada | $36 |
| Geron | Meals · 2025-10-22 | Rytelo | $31 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-21 | Tagrisso | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-20 | Enhertu | $29 |
| Celgene | Meals · 2025-10-17 | Breyanzi | $31 |
| Pfizer | Meals · 2025-10-13 | Padcev | $34 |
| Array Biopharma | Meals · 2025-10-13 | Braftovi | $26 |
| Celgene | Meals · 2025-10-10 | Reblozyl | $1 |
| Celgene | Meals · 2025-10-10 | Reblozyl | $31 |
| Merck Sharp & Dohme | Meals · 2025-10-07 | Keytruda | $14 |
| Janssen Biotech | Meals · 2025-10-02 | Tecvayli | $28 |
| Karyopharm Therapeutics | Meals · 2025-10-01 | Xpovio | $21 |
| Eisai | Meals · 2025-09-29 | Lenvima | $24 |
| Fennec Pharmaceuticals | Meals · 2025-09-17 | Fyarro | $21 |
| Celgene | Meals · 2025-08-25 | Reblozyl | $26 |
| Pharmacosmos Therapeutics | Meals · 2025-08-15 | Monoferric | $24 |
| Incyte | Meals · 2025-08-14 | Monjuvi | $25 |
| Daiichi Sankyo | Meals · 2025-08-12 | Enhertu | $6 |
| Lilly USA | Meals · 2025-08-08 | Jaypirca | $33 |
| Pfizer | Meals · 2025-08-06 | Ibrance | $34 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-05 | Opdivo | $26 |
| Celgene | Meals · 2025-08-04 | Reblozyl | $25 |
| GlaxoSmithKline | Meals · 2025-08-02 | Ojjaara | $22 |
| Iovance Biotherapeutics | Meals · 2025-07-31 | Amtagvi | $23 |
| Daiichi Sankyo | Meals · 2025-07-30 | Enhertu | $5 |
| Daiichi Sankyo | Meals · 2025-07-30 | Enhertu | $3 |
| Daiichi Sankyo | Meals · 2025-07-30 | Enhertu | $5 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-29 | Calquence | $27 |
| Kite Pharma | Meals · 2025-07-28 | Yescarta | $18 |
| Merck Sharp & Dohme | Meals · 2025-07-24 | Keytruda | $30 |
| GlaxoSmithKline | Meals · 2025-07-23 | Jemperli | $29 |
| Merck Sharp & Dohme | Meals · 2025-07-23 | Keytruda | $32 |
| Servier Pharmaceuticals | Meals · 2025-07-21 | Voranigo | $22 |
| Agios Pharmaceuticals | Meals · 2025-07-18 | Pyrukynd | $30 |
| Geron | Meals · 2025-07-16 | Rytelo | $34 |
| Daiichi Sankyo | Meals · 2025-07-15 | Datroway | $19 |
| Genzyme | Meals · 2025-07-15 | None | $17 |
| Recordati Rare Diseases Inc. | Meals · 2025-07-09 | Sylvant | $17 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-07 | Opdivo | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-03 | Lynparza | $25 |
| Janssen Biotech | Meals · 2025-07-02 | Tecvayli | $30 |
| Janssen Biotech | Meals · 2025-07-01 | Tecvayli | $1 |
| GlaxoSmithKline | Meals · 2025-07-01 | Jemperli | $11 |
| Legend Biotech USA | Meals · 2025-07-01 | Carvykti | $31 |
| Abbvie | Meals · 2025-06-30 | Imbruvica | $25 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-06-27 | Fruzaqla | $28 |
| Janssen Biotech | Meals · 2025-06-25 | Darzalex | $34 |
| Abbvie | Meals · 2025-06-23 | Imbruvica | $17 |
| SpringWorks Therapeutics | Meals · 2025-06-23 | Gomekli | $28 |
| Acrotech Biopharma | Meals · 2025-06-20 | Beleodaq | $21 |
| Eisai | Meals · 2025-06-19 | Lenvima | $24 |
| GlaxoSmithKline | Meals · 2025-06-18 | Jemperli | $32 |
| Puma Biotechnology | Meals · 2025-06-17 | Nerlynx | $28 |
| Merck Sharp & Dohme | Meals · 2025-06-16 | Keytruda | $32 |
| Celgene | Meals · 2025-06-12 | Reblozyl | $27 |
| Pharmacosmos Therapeutics | Meals · 2025-06-12 | Monoferric | $31 |
| Celgene | Meals · 2025-06-09 | Reblozyl | $28 |
| Celgene | Meals · 2025-06-06 | Reblozyl | $32 |
| Celgene | Meals · 2025-06-06 | Reblozyl | $1 |
| Janssen Biotech | Meals · 2025-06-04 | Darzalex | $37 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-03 | Tagrisso | $28 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-30 | Opdivo | $18 |
| Astellas Pharma US | Meals · 2025-05-29 | Vyloy | $20 |
| Janssen Biotech | Meals · 2025-05-28 | Erleada | $25 |
| Pfizer | Meals · 2025-05-28 | Elrexfio | $7 |
| BeOne Medicines USA | Meals · 2025-05-27 | Brukinsa | $23 |
| BeOne Medicines USA | Meals · 2025-05-22 | Tevimbra | $31 |
| Jazz Pharmaceuticals | Meals · 2025-05-20 | Ziihera | $40 |
| Janssen Biotech | Meals · 2025-05-17 | Rybrevant | $35 |
| Pfizer | Meals · 2025-05-16 | Ibrance | $28 |
| Pfizer | Meals · 2025-05-15 | Xtandi | $16 |
| Merck Sharp & Dohme | Meals · 2025-05-14 | Keytruda | $30 |
| SpringWorks Therapeutics | Meals · 2025-05-13 | Ogsiveo | $15 |
| TerSera Therapeutics | Meals · 2025-05-12 | Xermelo | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-02 | Calquence | $26 |
| Pfizer | Meals · 2025-05-01 | Elrexfio | $21 |
| Invivyd | Meals · 2025-04-29 | Pemgarda | $31 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-28 | Calquence | $24 |
| AstraZeneca Pharmaceuticals LP | Education · 2025-04-28 | None | $23 |
| GlaxoSmithKline | Meals · 2025-04-24 | Ojjaara | $19 |
| Iovance Biotherapeutics | Meals · 2025-04-24 | Amtagvi | $26 |
| GlaxoSmithKline | Meals · 2025-04-23 | Jemperli | $25 |
| Celgene | Meals · 2025-04-22 | Reblozyl | $28 |
| Exelixis | Meals · 2025-04-21 | Cabometyx | $45 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-04-21 | Iclusig | $1 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-04-21 | Ninlaro | $29 |
| Merck Sharp & Dohme | Meals · 2025-04-17 | Keytruda | $32 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-04-16 | Ninlaro | $1 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-04-16 | Iclusig | $22 |
| Daiichi Sankyo | Meals · 2025-04-15 | Enhertu | $12 |
| Genentech USA | Meals · 2025-04-15 | Polivy | $23 |
| Janssen Biotech | Meals · 2025-04-14 | Tecvayli | $33 |
| Janssen Biotech | Meals · 2025-04-14 | Tecvayli | $2 |
| Spectrum Pharmaceuticals | Meals · 2025-04-09 | Rolvedon | $31 |
| Merck Sharp & Dohme | Meals · 2025-04-08 | Keytruda | $16 |
| Kite Pharma | Meals · 2025-04-07 | Yescarta | $21 |
| Sobi | Meals · 2025-04-04 | Vonjo | $32 |
| Puma Biotechnology | Meals · 2025-04-03 | Nerlynx | $27 |
| Abbvie | Meals · 2025-04-01 | Imbruvica | $24 |
| Deciphera Pharmaceuticals | Meals · 2025-03-31 | Qinlock | $35 |
| Genentech USA | Meals · 2025-03-28 | Venclexta | $34 |
| Syndax Pharmaceuticals | Meals · 2025-03-27 | None | $26 |
| Gilead Sciences | Meals · 2025-03-26 | Trodelvy | $20 |
| Genmab U.S. | Meals · 2025-03-25 | Epkinly | $26 |
| Array Biopharma | Meals · 2025-03-24 | Xalkori | $12 |
| Merck Sharp & Dohme | Meals · 2025-03-21 | Keytruda | $33 |
| Celgene | Meals · 2025-03-20 | Reblozyl | $19 |
| Genzyme | Meals · 2025-03-19 | Sarclisa | $33 |
| Astellas Pharma US | Meals · 2025-03-17 | Vyloy | $21 |
| Regeneron Healthcare Solutions | Meals · 2025-03-12 | Libtayo | $35 |
| GlaxoSmithKline | Meals · 2025-03-11 | Jemperli | $30 |
| Incyte | Meals · 2025-03-11 | Jakafi | $28 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-10 | Lynparza | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-07 | Lynparza | $21 |
| PharmaEssentia USA | Meals · 2025-03-06 | Besremi | $29 |
| Lilly USA | Meals · 2025-03-04 | Verzenio | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-02 | Tagrisso | $40 |
| Merck Sharp & Dohme | Meals · 2025-02-26 | Keytruda | $34 |
| Daiichi Sankyo | Meals · 2025-02-25 | Enhertu | $14 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-24 | Lynparza | $20 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-22 | Lynparza | $12 |
| Astellas Pharma US | Meals · 2025-02-21 | Vyloy | $20 |
| Legend Biotech USA | Meals · 2025-02-20 | Carvykti | $27 |
| Daiichi Sankyo | Meals · 2025-02-19 | Enhertu | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-19 | Calquence | $18 |
| Eisai | Meals · 2025-02-18 | Lenvima | $27 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-14 | Ninlaro | $4 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-14 | Ninlaro | $17 |
| Lilly USA | Meals · 2025-02-13 | Verzenio | $29 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-11 | Opdivo | $19 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-10 | Fruzaqla | $2 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-10 | Fruzaqla | $29 |
| Pfizer | Meals · 2025-02-08 | Xtandi | $18 |
| Novartis Pharmaceuticals | Meals · 2025-02-07 | Pluvicto | $25 |
| Pfizer | Meals · 2025-02-06 | Xtandi | $19 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-05 | Ninlaro | $21 |
| Agios Pharmaceuticals | Meals · 2025-02-04 | Pyrukynd | $29 |
| Servier Pharmaceuticals | Meals · 2025-02-03 | None | $25 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-30 | Opdivo | $20 |
| Merck Sharp & Dohme | Meals · 2025-01-29 | Keytruda | $21 |
| GlaxoSmithKline | Meals · 2025-01-28 | Ojjaara | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-27 | Calquence | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-24 | Calquence | $30 |
| Genzyme | Meals · 2025-01-23 | Sarclisa | $26 |
| Merck Sharp & Dohme | Meals · 2025-01-22 | Keytruda | $33 |
| Celgene | Meals · 2025-01-21 | Reblozyl | $20 |
| Daiichi Sankyo | Meals · 2025-01-17 | Enhertu | $30 |
| Daiichi Sankyo | Meals · 2025-01-17 | Enhertu | $1 |
| Celgene | Meals · 2025-01-16 | Reblozyl | $29 |
| Celgene | Meals · 2025-01-16 | Reblozyl | $1 |
| BeiGene USA | Meals · 2025-01-15 | Brukinsa | $24 |
| Gilead Sciences | Meals · 2025-01-14 | Trodelvy | $23 |
| Ethicon | Meals · 2025-01-13 | Monarch Platform | $26 |
| Genentech USA | Meals · 2025-01-13 | Columvi | $27 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-09 | Opdivo | $1 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-09 | Opdivo | $16 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $4,343
| Pfizer | Ibrance | $577 | 32 payments
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $333 | 14 payments
|
| Abbvie | Venclexta | $319 | 13 payments
|
| Takeda Pharmaceuticals U.S.A. | Fruzaqla | $287 | 21 payments
|
| GlaxoSmithKline | Ojjaara | $272 | 16 payments
|
| Novartis Pharmaceuticals | Scemblix | $180 | 6 payments
|
| Celgene | Reblozyl | $169 | 8 payments
|
| Merck Sharp & Dohme | Keytruda | $159 | 6 payments
|
| Janssen Biotech | Rybrevant | $137 | 6 payments
|
| Gilead Sciences | None | $136 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $129 | 6 payments
|
| Array Biopharma | Braftovi | $101 | 4 payments
|
| EMD Serono | None | $100 | 4 payments
|
| Karyopharm Therapeutics | Xpovio | $90 | 3 payments
|
| Incyte | Monjuvi | $85 | 5 payments
|
| Daiichi Sankyo | Enhertu | $82 | 4 payments
|
| Octapharma USA | Octagam Immune Globulin (Human) | $72 | 2 payments
|
| Servier Pharmaceuticals | Tibsovo | $68 | 3 payments
|
| Stemline Therapeutics | Orserdu | $66 | 2 payments
|
| Regeneron Healthcare Solutions | Libtayo | $66 | 2 payments
|
| Astellas Pharma US | Xospata | $57 | 3 payments
|
| SpringWorks Therapeutics | Ogsiveo | $57 | 3 payments
|
| Genzyme | Sarclisa | $56 | 2 payments
|
| Eisai | Lenvima | $54 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $54 | 2 payments
|
| Genentech USA | Alecensa | $51 | 2 payments
|
| Taiho Oncology | Lonsurf | $50 | 2 payments
|
| Acrotech Biopharma | Beleodaq | $47 | 2 payments
|
| Exelixis | Cabometyx | $46 | 1 payment
|
| Jazz Pharmaceuticals | Zepzelca | $38 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $37 | 1 payment
|
| Ipsen Biopharmaceuticals | Onivyde | $33 | 1 payment
|
| Geron | Rytelo | $33 | 1 payment
|
| Sobi | Vonjo | $33 | 1 payment
|
| Blueprint Medicines | Ayvakit | $30 | 1 payment
|
| Puma Biotechnology | None | $26 | 1 payment
|
| Agios Pharmaceuticals | Pyrukynd | $25 | 1 payment
|
| Genmab U.S. | Epkinly | $25 | 1 payment
|
| Kyowa Kirin | Poteligeo | $22 | 1 payment
|
| Tactile Systems Technology | Flexitouch Plus | $22 | 1 payment
|
| BeiGene USA | Brukinsa | $22 | 1 payment
|
| Myriad Genetic Laboratories | Myrisk | $21 | 1 payment
|
| Apellis Pharmaceuticals | Empaveli | $21 | 1 payment
|
| Kite Pharma | Yescarta | $20 | 1 payment
|
| Sun Pharmaceutical Industries | Odomzo | $19 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $18 | 1 payment
|
2023: $4,392
| Pfizer | Ibrance | $320 | 19 payments
|
| Novartis Pharmaceuticals | Kisqali | $301 | 11 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $265 | 16 payments
|
| Merck Sharp & Dohme | Keytruda | $242 | 9 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $229 | 10 payments
|
| Janssen Biotech | Rybrevant | $207 | 13 payments
|
| Genentech USA | Tecentriq | $176 | 6 payments
|
| Astellas Pharma US | Xospata | $167 | 6 payments
|
| Tactile Systems Technology | Flexitouch Plus | $141 | 2 payments
|
| Seagen | Tukysa | $132 | 5 payments
|
| Celgene | Reblozyl | $131 | 6 payments
|
| GlaxoSmithKline | Zejula | $130 | 7 payments
|
| Eisai | Lenvima | $122 | 5 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $116 | 5 payments
|
| Genzyme | Sarclisa | $116 | 4 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $111 | 5 payments
|
| Gilead Sciences | Trodelvy | $106 | 5 payments
|
| Taiho Oncology | Lonsurf | $99 | 5 payments
|
| Pharmacosmos Therapeutics | Monoferric | $93 | 4 payments
|
| Daiichi Sankyo | Enhertu | $89 | 4 payments
|
| Array Biopharma | Lorbrena | $89 | 3 payments
|
| Lilly USA | Verzenio | $88 | 4 payments
|
| Kite Pharma | Yescarta | $81 | 4 payments
|
| Amgen | Lumakras | $76 | 4 payments
|
| Octapharma USA | Panzyga | $75 | 2 payments
|
| Mirati Therapeutics | Krazati | $62 | 3 payments
|
| Sobi | Doptelet | $48 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $47 | 2 payments
|
| Acrotech Biopharma | Beleodaq | $42 | 2 payments
|
| Apellis Pharmaceuticals | Empaveli | $41 | 2 payments
|
| Jazz Pharmaceuticals | Zepzelca | $37 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $31 | 1 payment
|
| AbbVie | Venclexta | $31 | 1 payment
|
| Stemline Therapeutics | Orserdu | $29 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $29 | 1 payment
|
| AVEO Pharmaceuticals | Fotivda | $29 | 1 payment
|
| Exelixis | Cabometyx | $27 | 1 payment
|
| MorphoSys US | Monjuvi | $24 | 1 payment
|
| Coherus Biosciences | Udenyca | $23 | 1 payment
|
| Myriad Genetic Laboratories | Precisetumor | $22 | 1 payment
|
| Foundation Medicine | None | $22 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $21 | 1 payment
|
| BeiGene USA | Brukinsa | $19 | 1 payment
|
| ADC Therapeutics America | None | $18 | 1 payment
|
| Heron Therapeutics | Sustol | $17 | 1 payment
|
| Servier Pharmaceuticals | Tibsovo | $17 | 1 payment
|
| EMD Serono | Tepmetko | $16 | 1 payment
|
| TerSera Therapeutics | Zoladex | $16 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $14 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $9 | 1 payment
|
2022: $2,923
| Novartis Pharmaceuticals | Kisqali | $255 | 13 payments
|
| Astellas Pharma US | Xospata | $250 | 7 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $223 | 8 payments
|
| Kite Pharma | None | $182 | 13 payments
|
| Genzyme | Sarclisa | $175 | 6 payments
|
| GlaxoSmithKline | Zejula | $175 | 7 payments
|
| Seagen | Tukysa | $154 | 7 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $152 | 8 payments
|
| Pfizer | Ibrance | $127 | 8 payments
|
| Array Biopharma | Braftovi | $113 | 6 payments
|
| Celgene | Pomalyst | $99 | 5 payments
|
| Myovant Sciences | Orgovyx | $83 | 3 payments
|
| Amgen | Kyprolis | $79 | 3 payments
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $63 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $61 | 3 payments
|
| Lilly USA | Verzenio | $60 | 2 payments
|
| Gilead Sciences | Trodelvy | $58 | 3 payments
|
| Janssen Biotech | Rybrevant | $55 | 3 payments
|
| Genentech USA | Polivy | $49 | 2 payments
|
| Ethicon US | Vistaseal | $47 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $43 | 2 payments
|
| Rigel Pharmaceuticals | Tavalisse | $41 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Xofigo | $39 | 2 payments
|
| Kyowa Kirin | Poteligeo | $36 | 2 payments
|
| Taiho Oncology | Lonsurf | $36 | 2 payments
|
| PharmaEssentia USA | Besremi | $32 | 1 payment
|
| Eisai | Lenvima | $31 | 1 payment
|
| Exelixis | Cabometyx | $28 | 1 payment
|
| Abbvie | Lupron Depot | $27 | 1 payment
|
| Servier Pharmaceuticals | Tibsovo | $25 | 1 payment
|
| Global Blood Therapeutics | Oxbryta | $24 | 1 payment
|
| CTI BioPharma | Vonjo | $24 | 1 payment
|
| MorphoSys US | Monjuvi | $23 | 1 payment
|
| Incyte | Monjuvi | $18 | 1 payment
|
| Acrotech Biopharma | Beleodaq | $17 | 1 payment
|
| Blue Earth Diagnostics | Axumin | $17 | 1 payment
|
2021: $1,611
| Seagen | Padcev | $150 | 6 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $140 | 8 payments
|
| Novartis Pharmaceuticals | Mekinist | $138 | 7 payments
|
| Pfizer | Inlyta | $104 | 5 payments
|
| Sanofi-Aventis U.S. | Elitek | $77 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $76 | 3 payments
|
| Lilly USA | Verzenio | $68 | 4 payments
|
| Amgen | Lumakras | $60 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $53 | 3 payments
|
| Janssen Biotech | Darzalex | $52 | 3 payments
|
| Eisai | Lenvima | $43 | 2 payments
|
| Taiho Oncology | Lonsurf | $42 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $39 | 2 payments
|
| Genzyme | Elitek | $36 | 2 payments
|
| Epizyme | Tazverik | $34 | 2 payments
|
| Celgene | Pomalyst | $33 | 2 payments
|
| Astellas Pharma US | Xospata | $33 | 2 payments
|
| Myovant Sciences | Orgovyx | $31 | 2 payments
|
| Servier Pharmaceuticals | Tibsovo | $25 | 1 payment
|
| Dova Pharmaceuticals | Doptelet | $24 | 1 payment
|
| Aveo Pharmaceuticals | Fotivda | $23 | 1 payment
|
| Rigel Pharmaceuticals | Tavalisse | $23 | 1 payment
|
| Puma Biotechnology | Nerlynx | $23 | 1 payment
|
| Daiichi Sankyo | Injectafer | $22 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Cosela | $22 | 1 payment
|
| Kite Pharma | None | $21 | 1 payment
|
| GlaxoSmithKline | Zejula | $21 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $21 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Vitrakvi | $21 | 1 payment
|
| Kyowa Kirin | Poteligeo | $20 | 1 payment
|
| Clovis Oncology | None | $20 | 1 payment
|
| EMD Serono | None | $19 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $19 | 1 payment
|
| Incyte | Monjuvi | $18 | 1 payment
|
| Organon | Ontruzant | $17 | 1 payment
|
| BeiGene USA | Brukinsa | $16 | 1 payment
|
| Array Biopharma | Braftovi | $15 | 1 payment
|
| Genentech USA | Gazyva | $13 | 1 payment
|
2020: $4,277
| Agios Pharmaceuticals | Tibsovo | $4,122 | 10 payments
|
| Daiichi Sankyo | Enhertu | $37 | 1 payment
|
| Amgen | Kyprolis | $37 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $36 | 2 payments
|
| BeiGene USA | Brukinsa | $18 | 1 payment
|
| Kite Pharma | Yescarta | $16 | 1 payment
|
| Verastem | Copiktra | $11 | 1 payment
|
2019: $697
| Amgen | Vectibix | $154 | 3 payments
|
| Foundation Medicine | Foundationone | $131 | 1 payment
|
| Sanofi-Aventis U.S. | Jevtana | $100 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $88 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $30 | 2 payments
|
| Tesaro | Zejula | $28 | 1 payment
|
| Pfizer | Ibrance | $22 | 2 payments
|
| Agios Pharmaceuticals | Tibsovo | $17 | 1 payment
|
| AbbVie | Venclexta | $17 | 1 payment
|
| Janssen Biotech | Balversa | $16 | 1 payment
|
| Incyte | Jakafi | $15 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $14 | 1 payment
|
| Novartis Pharmaceuticals | Promacta | $14 | 1 payment
|
| Genzyme | Jevtana | $14 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $13 | 1 payment
|
| TerSera Therapeutics | Zoladex | $12 | 1 payment
|
| AMAG Pharmaceuticals | Feraheme | $11 | 1 payment
|
Professional record
- NPI
- 1659634772
- Licence
- MI 4301107781
- Group
- Epic Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 2345 Country Hills Dr, Antioch, CA, 94509
- NPI first listed
- 2012-06-22
- NPI last updated
- 2021-12-09
- NPI record certified
- 2021-12-09
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1480 64th St Ste 100, Emeryville, CA, 94608